Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Ovarian Neoplasms 4Prostatic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 1SCLC,Extensive Stage 1Prostatic Neoplasms, Castration-Resistant 1Ovarian Carcinosarcoma 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Metastatic Castration-sensitive Prostate Cancer 1Laryngeal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Biliary Tract Neoplasms 1

Interventions

Biopsy 5X-Rays 4Specimen Handling 4Phantoms, Imaging 4Nuclear Medicine Department, Hospital 4Magnetic Resonance Spectroscopy 4larotrectinib 2erdafitinib 2ensartinib 2ulixertinib 1tipifarnib 1tazemetostat 1selpercatinib 1palbociclib 1olaparib 1niraparib 1ivosidenib 1elacestrant 1cabozantinib 1alectinib 1abemaciclib 1Vincristine 1Vinblastine 1Vemurafenib 1Topotecan 1Temozolomide 1RAD1901 1Methotrexate 1LY3023414 1Induction Chemotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × niraparib × 30 days × Clear all
NCT04992013 2026-06-01

Niraparib in Tumors Metastatic to the CNS

Massachusetts General Hospital

Phase 2 Active not recruiting
20 enrolled
CNS

Neoplasm Metastasis, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡